Enveric Biosciences (ENVB) News Today → Where AI is REALLY Going Next (From InvestorPlace) (Ad) Free envb Stock Alerts $0.63 0.00 (0.00%) (As of 06/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 28 at 8:00 AM | globenewswire.comDiamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)June 25, 2024 | businesswire.comEnveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development CandidateMay 30, 2024 | businesswire.comEnveric Biosciences to Participate in BIO International Convention 2024May 16, 2024 | benzinga.com'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On HandMay 15, 2024 | msn.comEnveric Biosciences GAAP EPS of -$0.61May 15, 2024 | businesswire.comEnveric Biosciences Reports First Quarter 2024 Financial and Corporate ResultsMay 14, 2024 | msn.comMicrodosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug CandidateMay 14, 2024 | businesswire.comEnveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health DisordersMay 8, 2024 | msn.comCannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented MethodsMay 8, 2024 | businesswire.comEnveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using CannabinoidsMarch 27, 2024 | benzinga.comEnveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future GrowthMarch 21, 2024 | uk.investing.comEnveric Biosciences Inc (ENVB)March 19, 2024 | msn.comWhy Is Anxiety/Addiction-Focused Enveric Biosciences Stock Trading Higher Tuesday?March 19, 2024 | msn.comEnveric gains on out-licensing deal of new chemical entities for joint disease treatmentsMarch 19, 2024 | finance.yahoo.comEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint DiseaseMarch 12, 2024 | finance.yahoo.comEnveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term SheetsMarch 4, 2024 | msn.comPsyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And MoreFebruary 29, 2024 | investorplace.comWhy Is Enveric Biosciences (ENVB) Stock Up 120% Today?February 29, 2024 | markets.businessinsider.comEnveric Signs Term Sheets To Pursue Out-licensing Of Three Classes Of CompoundsFebruary 29, 2024 | businesswire.comEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of CompoundsFebruary 26, 2024 | finance.yahoo.comCORRECTION – Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)February 23, 2024 | markets.businessinsider.comEnveric Biosciences To Sell Cannabinoid-Related Cancer Intellectual Property; Stock Up In Pre-MarketFebruary 23, 2024 | businesswire.comEnveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual PropertyFebruary 21, 2024 | msn.comEnveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical CompoundsFebruary 21, 2024 | finance.yahoo.comEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health DisordersFebruary 21, 2024 | businesswire.comEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health DisordersFebruary 12, 2024 | msn.comPsychedelic stocks gain after FDA priority review for MDMA therapyFebruary 10, 2024 | msn.comEnveric Biosciences Granted Extension to Avoid Nasdaq DelistingJanuary 3, 2024 | finance.yahoo.comEnveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 SeriesDecember 28, 2023 | msn.comEnveric stock jumps 13% on pipeline updateDecember 28, 2023 | marketwatch.comEnveric Biosciences Shares Rise 7% After Selecting Lead Drug CandidateDecember 28, 2023 | finance.yahoo.comEnveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 SeriesDecember 27, 2023 | finance.yahoo.comEnveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373December 20, 2023 | finance.yahoo.comBears are Losing Control Over Enveric Biosciences, Inc. (ENVB), Here's Why It's a 'Buy' NowDecember 20, 2023 | marketbeat.com5 Biotech stocks tapping into unmet mental health treatment needs (ENVB)Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.December 20, 2023 | finance.yahoo.comEnveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024"December 5, 2023 | finance.yahoo.comEnveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived CompoundsNovember 29, 2023 | finance.yahoo.comEnveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin DerivativesNovember 24, 2023 | finance.yahoo.comEnveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)November 13, 2023 | finance.yahoo.comEnveric Biosciences Reports Third Quarter 2023 Corporate and Financial ResultsOctober 31, 2023 | finance.yahoo.comEnveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of PsilocinOctober 20, 2023 | finance.yahoo.comEnveric Biosciences to Present at the Centurion One 5th Global SummitOctober 18, 2023 | finance.yahoo.comEnveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric DisordersOctober 11, 2023 | finance.yahoo.comEnveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development SummitSeptember 27, 2023 | finance.yahoo.comEnveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological ChemistrySeptember 21, 2023 | benzinga.comEnveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details HereSeptember 20, 2023 | finance.yahoo.comEnveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug CandidatesSeptember 11, 2023 | finance.yahoo.comEnveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine DerivativesSeptember 5, 2023 | finance.yahoo.comEnveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine DerivativesAugust 30, 2023 | finance.yahoo.comEnveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address Where AI is REALLY Going Next (Ad)Buying Nvidia was a good idea – twenty years ago when I first recommended it (for up to 37,000% gains). But chipmakers are the FIRST GENERATION of AI. And just like the dot-com era… That’s NOT where the big money will be made. Here’s what I’m recommending now (includes 2 stock tickers). ENVB Media Mentions By Week ENVB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENVB News Sentiment▼0.720.84▲Average Medical News Sentiment ENVB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENVB Articles This Week▼41▲ENVB Articles Average Week Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: APLM News LUMO News SYBX News FBRX News VINC News VBIV News GLYC News SNSE News TLPH News AYTU News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENVB) was last updated on 6/30/2024 by MarketBeat.com Staff From Our PartnersA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
